PARTNERSHIP WITH THE
Institute of Bioorganic Chemistry
of the Polish Academy of Sciences
Innovation in products
Establishing the Research and Development Laboratory for Medicofarma S.A.
The project involves establishing R&D infrastructure through investment in devices and equipment to be used in carrying out research and development works for the purpose of developing innovative products and services.The main aim of the project is to establish the research and development laboratory for Medicofarma S.A. and carrying out R&D works in accordance with the developed research agenda to achieve innovation in products and processes.
Innovation in products and processes – development
and implementation of 5 dietary supplements
In regards to achieving product innovation, the subject matter and goal of the research effort is the development and subsequent implementation of 5 dietary supplements containing vitamins and minerals within a controlled release formulation.It is planned as a unique product for patients looking for a modern formulation with improved effect and absorption. The developed pharmaceuticals will be part of the following product groups: fatigue treatment, immunity boosters, stimulants and intellectual capacity boosters.Research results will be used to develop manufacturing processes and formulation for the new generation of the 5 innovative dietary supplement products.
The planned products are unique in III ways:
- unique composition, a blend of active substances – product innovation
- advanced technology, releases groups of constituents in different time stages – process innovation
- composition is fully safe for the consumer in regards to epigenetic changes which might lead to carcinogenesis.
PARTNERSHIP WITH THE PAS INSTITUTE OF BIOORGANIC CHEMISTRY
Establishing the Research and Development
Laboratory for Medicofarma S.A.
Medicofarma entered into a partnership with the PAS Institute of Bioorganic Chemistry (ICHB PAN) for the purpose of carrying out research and development works to identify epigenetic changes (DNA modification) effected by small-particle active substances in dietary supplements. Based on this data, new and innovative dietary supplements based on epigenetic profiling were designed. The above goal was implemented through use of the most advanced methods of epigenomics in analyzing global DNA methylation, important from the standpoint of human health.
Implementation and launch of manufacturing
Implementing the results of R&D works and starting the manufacturing of innovative dermocosmetics with the patented 4-N-Furfuryl Cytosine molecule.
The project implements in-house manufacturing based on R&D results purchased from the PAS Institute of Bioorganic Chemistry, subject to patent protection in Poland and abroad, together with own research carried out by a renowned doctor of aesthetic medicine. Medicofarma SA being well positioned in the pharmacy business, the results of the above works allow to introduce dermo-cosmetic preparations for sale, this product uses a patented anti-aging formulation with 4-N-Furfuryl Cytosine which increases the life of fibroblasts and prevents the damage by free radicals. It is a natural substance, a growth hormone of plant origin, able to delay and prevent adverse changes caused by skin aging. It is an effective antioxidant which halts the degradation of skin cells with a beneficial effect on genetic material by stimulating DNA repair without any side effects. Laboratory tests confirm there is no cytotoxicity or cytostasis. Application testing indicates improved effects of cosmetic preparations based on 4-N-Furfuryl Cytosine in comparison to other products available on the market. New products will feature improved bioaccessibility and persistence of the active substance together with a higher level of safety and natural origin of the composition.The implementation of this project allows commercialization of the research effort by a respected institute and making use of the competitive advantages of Medicofarma.
To this end, Medicofarma purchased an exclusive license for the patent No.: “Method of obtaining of 4-N-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-N-furfuryl cytosine and/or its derivatives in the manufacture of anti-aging composition” from the PAS Institute of Bioorganic Chemistry.
Generic RT-PCR test under the name MediPAN-2G+FAST COVID
As a result of a fruitful partnership with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences, the first Polish genetic test kit for detecting SARS-CoV-2 is introduced to the market. Scientists from the Polish Academy of Sciences Institute of Bioorganic Chemistry in Poznań developed the MediPAN-2G+GAST COVID test which allows to detect the two specific genes of the coronavirus. Medicofarma S.A. took up the production of the pilot batch and moved to full scale production of the test kits. Intensive research efforts by scientists as well as the capabilities of our manufacturing facilities allowed introducing one of the fastest tests of this type into the market, with very high accuracy of the virus detection reaction.
MediPAN COVID SARS-CoV-2 is the first Polish genetic test for detecting. The Polish Institute of Sciences Institute of Bioorganic Chemistry is the leading scientific center, specializing in RNA research, including the study of viruses with RNA in their genetic composition. Such viruses include the SARS-CoV-2 coronavirus responsible for COVID-19. In the course of the research works, three generations of the genetic test to detect the SARS-CoV-2 virus were developed.